Sugi Predict

Sugi Predict / Compounds / SCHEMBL835443

SCHEMBL835443

SCHEMBL835443

C=CCn1c(Cl)nc2[nH]c(=O)[nH]c(=O)c21

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 1/20 0.40
▸ CYP3A4 P08684 2/20 0.38
▸ USP2 O75604 2/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ ADORA3 P0DMS8 1/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ GDA Q9Y2T3 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ CSNK2A2 P19784 1/20 0.35
▸ CSNK2B P67870 1/20 0.35
▸ CSNK2A1 P68400 1/20 0.35
▸ POLB P06746 1/20 0.34
▸ BRDT Q58F21 1/20 0.34
▸ NOD1 Q9Y239 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL874548 0.84 ALDH1A1 (0.39) DPP4CYP3A4USP2ALDH1A1ADORA3
SCHEMBL18440925 0.84 ALDH1A1 (0.36) DPP4CYP3A4USP2ALDH1A1ADORA3
SCHEMBL23255513 0.80 NOD1 (0.40) DPP4CYP3A4ALDH1A1GDALMNA
SCHEMBL6112180 0.77 NOD1 (0.45) USP2ALDH1A1LMNANOD1MEN1
SCHEMBL3177873 0.76 USP2 (0.47) CYP3A4USP2ALDH1A1ADORA3ADORA2B
SCHEMBL16028807 0.74 DPP4 (0.52) DPP4CYP3A4ALDH1A1LMNAPOLB
SCHEMBL20432200 0.74 DPP4 (0.65) DPP4ALDH1A1ADORA3PKMPOLB
SCHEMBL5719366 0.73 ALDH1A1 (0.64) USP2ALDH1A1LMNAPKMPOLB
SCHEMBL3503364 0.72 MEN1 (0.44) CYP3A4USP2ALDH1A1ADORA3ADORA2B
SCHEMBL836795 0.72 ALDH1A1 (0.49) USP2ALDH1A1LMNAPKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3251675-B1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE SHANTON PHARMA PTE LTD (SG) 2021-04-21 — — EP disclosed
US-10322132-B2 Prevention or treatment of uratic or gouty diseases SHANTON PHARMA CO., LTD (CN) 2019-06-18 — — US disclosed
EP-3251675-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE Shanton Pharma Co., Ltd. (CN) 2017-12-06 — — EP disclosed
US-20170326148-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE Shanton Pharma Pte. Ltd. (SG) 2017-11-16 — — US disclosed
US-20170326148-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE Shanton Pharma Pte. Ltd. (SG) 2017-11-16 — — US disclosed
US-20170027945-A1 Novel Compounds GLAXOSMITHKLINE LLC 2017-02-02 — — US disclosed
US-20170027945-A1 Novel Compounds GLAXOSMITHKLINE LLC 2017-02-02 — — US disclosed
WO-2016119570-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE 上海珊顿医药科技有限公司 2016-08-04 — — WO disclosed
US-20150366870-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE LLC 2015-12-24 — — US disclosed
US-20150366870-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE LLC 2015-12-24 — — US disclosed
US-20100010021-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED 2010-01-14 — — US disclosed
EP-1912992-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SmithKline Beecham Corporation (US) 2008-04-23 — — EP disclosed
EP-1912991-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SmithKline Beecham Corporation (US) 2008-04-23 — — EP disclosed
US-20070135456-A1 Medicaments with hm74a receptor activity GLAXOSMITHKLINE LLC 2007-06-14 — — US disclosed
US-20070135456-A1 Medicaments with hm74a receptor activity GLAXOSMITHKLINE LLC 2007-06-14 — — US disclosed
US-20070135456-A1 Medicaments with hm74a receptor activity GLAXOSMITHKLINE LLC 2007-06-14 — — US disclosed
EP-1781657-A2 MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-05-09 — — EP disclosed
WO-2007017261-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 — — WO disclosed
WO-2007017262-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 — — WO disclosed
WO-2005077950-A2 MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135456-A1 Medicaments with hm74a receptor activity HCAR1, GPR84, HCAR3 DPP4 1119/4885CYP3A4 1101/4885USP2 3953/4885
US-20170027945-A1 Novel Compounds GPR68, GPR84, GPR88 DPP4 1270/4885CYP3A4 2453/4885USP2 3916/4885
US-20170326148-A1 PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE NLRP3, REN, SLC5A1 DPP4 1159/4885CYP3A4 1639/4885USP2 3297/4885
US-10322132-B2 Prevention or treatment of uratic or gouty diseases REN, NLRP3, SLC5A1 DPP4 774/4885CYP3A4 1463/4885USP2 3505/4885
US-20150366870-A1 NOVEL COMPOUNDS GPR68, GPR84, GPR88 DPP4 1270/4885CYP3A4 2453/4885USP2 3916/4885
US-20100010021-A1 NOVEL COMPOUNDS HCAR1, XDH, GPR84 DPP4 1264/4885CYP3A4 709/4885USP2 4163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.